Ionis Pharmaceuticals (IONS) Non Operating Investment Income (2009 - 2026)

Ionis Pharmaceuticals' Non Operating Investment Income history runs 15 years deep, the most recent figure standing at $22.6 million for Q1 2026.

• In Q1 2026, Non Operating Investment Income rose 1143.58% year-over-year to $22.6 million; the TTM figure through Mar 2026 stood at $35.0 million (up 573.42% YoY), while the FY2025 annual figure was $10.2 million, up 453.76% from the prior year.
• Non Operating Investment Income was $22.6 million for Q1 2026 at Ionis Pharmaceuticals, up from $788000.0 in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $29.9 million in Q3 2025 to a low of -$18.3 million in Q2 2025.
• Historically, Non Operating Investment Income has averaged $1.2 million across 5 years, with a median of -$161000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Non Operating Investment Income tumbled 1495.03% in 2024, then surged 3302.5% in 2025.
• A 5-year view of Non Operating Investment Income shows it stood at $3.3 million in 2022, then plunged by 104.9% to -$161000.0 in 2023, then sank by 1495.03% to -$2.6 million in 2024, then jumped by 130.69% to $788000.0 in 2025, then surged by 2765.86% to $22.6 million in 2026.
• The last three Non Operating Investment Income figures came in at $22.6 million (Q1 2026), $788000.0 (Q4 2025), and $29.9 million (Q3 2025), per Business Quant data.